-+ 0.00%
-+ 0.00%
-+ 0.00%

SynAct Pharma partners with Hipolabor to develop, commercialize resomelagon for dengue in Brazil

PUBT·10/27/2026 13:58:40
Listen to the news
SynAct Pharma partners with Hipolabor to develop, commercialize resomelagon for dengue in Brazil
  • SynAct Pharma signed a co-development and commercialization agreement with Hipolabor Farmacêutica for resomelagon to treat dengue in Brazil.
  • The partners will split profits equally, with additional sales milestone payments linked to cumulative net sales of USD 200 million.
  • Development costs for securing Brazilian regulatory approval will be shared equally.
  • SynAct retains full control over resomelagon, including rights to pursue partnerships in other indications and territories.
  • RESOVIR-2 Part 1 results are expected in 2026 pending regulatory feedback; full-study topline results are expected in the second quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.